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MaOBJECTIVES The aim of this study was to assess outcomes after percutaneous coronary intervention (PCI) with
stents in patients treated with thoracic external beam radiation therapy (EBRT).
BACKGROUND Thoracic EBRT for cancer is associated with long-term cardiotoxic sequelae. The impact of EBRT
on patients requiring coronary stents is unclear.
METHODS We analyzed outcomes after PCI in cancer survivors treated with curative thoracic EBRT before and after
stenting between 1998 and 2012. Reference groups were propensity-matched cohorts with stenting but no EBRT.
Primary endpoint was target lesion revascularization (TLR), a clinical surrogate for restenosis. Secondary endpoints
included myocardial infarction (MI) and cardiac and overall mortality.
RESULTS We identiﬁed 115 patients treated with EBRT a median 3.6 years after stenting (group A) and 45 patients
treated with EBRT a median 2.2 years before stenting (group B). Long-term mean TLR rates in group A (3.2 vs. 6.6%;
hazard ratio: 0.6; 95% conﬁdence interval: 0.2 to 1.6; p ¼ 0.31) and group B (9.2 vs. 9.7%; hazard ratio: 1.2; 95%
conﬁdence interval: 0.4 to 3.4; p ¼ 0.79) were similar to rates in corresponding control patients (group A: 1,390 control
patients; group B: 439 control patients). Three years post-PCI, group A had higher overall mortality (48.6% vs. 13.9%;
p < 0.001) but not MI (4.8% vs. 4.3%; p ¼ 0.93) or cardiac mortality (2.3% vs. 3.6%; p ¼ 0.66) rates versus control
patients. There were no signiﬁcant differences in MI, cardiac, or overall mortality rates in group B.
CONCLUSIONS Thoracic EBRT is not associated with increased stent failure rates when used before or after PCI.
A history of PCI should not preclude the use of curative thoracic EBRT in cancer patients or vice versa. Optimal treatment
of cancer should be the goal. (J Am Coll Cardiol Intv 2014;7:1412–20) © 2014 by the American College of Cardiology
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AB BR E V I A T I O N S
AND ACRONYM S
BMS = bare-metal stent(s)
CAD = coronary artery disease
DES = drug-eluting stent(s)
EBRT = external beam
radiation therapy
IQR = interquartile range
MI = myocardial infarction
PCI = percutaneous coronary
intervention
TLR = target lesion
revascularization
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1413with an initial diagnosis of CAD, cancer develops,
requiring EBRT. Conversely, many cancer survivors
who received EBRT subsequently require PCI for
symptomatic CAD.
Despite the deleterious impact of EBRT on the heart
and concerns regarding impaired vascular healing,
radiation brachytherapy was used in the past as a
treatment for coronary restenosis with bare-metal
stents (BMS) (1,2). However, long-term follow-up
demonstrated a delayed risk of stent failure (3,4). This
observation raises the possibility that EBRT may
adversely affect outcomes in patients with coronary
stents, but there is a paucity of data on the subject.
Thus, the aim of this study was to assess clinical
outcomes after PCI with stents in cancer patients
treated with EBRT before or after the coronary
revascularization.METHODS
STUDY POPULATION. In this retrospective analysis,
patients referred to the Mayo Clinic in Rochester,
Minnesota, for curative thoracic EBRT for the treat-
ment of malignancy between March 1998 and
November 2012 who were also treated with PCI at our
institution during the same time interval, either
before or after EBRT, were included. The EBRT-
treated population was restricted to malignancies
that would result in signiﬁcant cardiac exposure.
These patients were then cross-referenced with the
Mayo Clinic PCI database. The patients were divided
into 2 groups: those who had PCI before EBRT (group
A) and those who had PCI after EBRT (group B). Two
separate control groups of propensity-matched pa-
tients who had PCI but no EBRT were identiﬁed for
comparison. The study was approved by the Mayo
Clinic’s Institutional Review Board.
PCI PROCEDURE. The Mayo Clinic PCI registry in-
cludes demographic, clinical, angiographic, and pro-
cedural data. Immediate and in-hospital events are
recorded, and each patient is surveyed by telephone
contact by trained research coordinators using a
standardized questionnaire at 6 months, 1 year, and
then annually after the procedure. All adverse events
are conﬁrmed by reviewing the medical records of the
patients followed at our institution and by contacting
the patients’ physicians and reviewing the hospital
records of patients followed elsewhere.
Only patients who had successful PCI with at least
1 BMS or drug-eluting stent (DES) were included.
All patients received dual-antiplatelet therapy for a
minimal duration of 1 month for a BMS and 12 months
in those treated with a DES. In the absence of anallergy or marked intolerance, lifelong aspirin
therapy was recommended.
RADIATION THERAPY. All patients had a
biopsy-conﬁrmed or radiographic (early-
stage non-small cell lung cancer) diagnosis of
malignancy and received EBRT with a cura-
tive intent. The malignancies included can-
cers of the lung (small cell or non-small cell),
breast, thymus, gastrointestinal tract (in-
cluding the biliary tree, stomach, esophagus,
and pancreas), and lymphoma. The majority
of patients had a cancer above the dia-
phragm. The TNM staging was assigned and
deﬁned according to the American Joint Committee
on Cancer Cancer Staging Manual, Sixth Edition (5).
The cancers were staged from I to IVA (stage IVA for
esophageal carcinoma is considered locally advanced
and potentially curable), with none of the cancers
having M1 staging (proven metastasis at initial diag-
nosis, usually noncurable by combined modalities
including radiation). The non-Hodgkin lymphoma
patients received a dose ranging from 35 to 70 Gy, and
the 3 Hodgkin patients received total radiation doses
of 24, 24, and 30.6 Gy, respectively. All EBRT simu-
lation plans were performed with computed to-
mography imaging. A radiation oncologist (T.T.S.)
reviewed each individual dosimetric plan and veriﬁed
cardiac involvement by EBRT. Fifteen cases of ste-
reotactic body radiation therapy (all for early-stage
lung cancers) and 11 cases of intensity-modulated
radiotherapy (a more modern radiation technique)
were included.
CARDIAC CLINICAL OUTCOMES. The primary out-
come of this study was target lesion revascularization
(TLR), a surrogate for clinically signiﬁcant stent ste-
nosis and deﬁned as any attempted percutaneous or
surgical revascularization of the target lesion at any
time after the initial procedure. Secondary outcomes
included MI, cardiac mortality, and all-cause mortal-
ity. MI was diagnosed in the presence of 2 of the
following 3 criteria: 1) typical chest pain for at least 20
min; 2) increase in creatine kinase (or the myocardial
band fraction) >2 times normal; and 3) a new Q-wave
on an electrocardiogram. Deaths were considered
cardiac if they were due to MI, sudden death (within
1 h of cardiac symptoms), or other cardiac causes
(e.g., congestive heart failure, arrhythmia).
STATISTICAL ANALYSIS. Continuous variables are
summarized as mean  SD unless otherwise noted;
discrete variables are summarized as frequency
(percentage). For both groups A and B, a propensity
score was developed to predict case membership
TABLE 1 Baseline Demographic and Clinical Characteristics, Presenting Characteristics at the Time of PCI, and Medications
at Hospital Discharge After PCI
PCI Before EBRT
(n ¼ 115)
Control Patients
(n ¼ 1,930) p Value
EBRT Before PCI
(n ¼ 45)
Control Patients
(n ¼ 439) p Value
Age, yrs 66.1  9.5 66.3  9.5 0.59 70.2  9.7 70.2  9.6 0.81
Male 50 (43) 839 (43) * 16 (36) 156 (36) *
Body mass index, kg/m2 29.4  5.9 29.5  6.2 0.76 29.7  6.8 29.4  5.9 0.78
Lifelong nonsmoker 34 (30) 554 (29) 0.96 17 (40) 183 (42) 0.84
Congestive heart failure 6 (5) 67 (4) 0.63 8 (18) 79 (18) 0.95
Diabetes mellitus 25 (22) 349 (18) 0.27 9 (20) 106 (24) 0.72
Hypertension 81 (74) 1,209 (65) 0.036 34 (76) 323 (77) 0.71
Hyperlipidemia 66 (65) 1,187 (68) 0.70 32 (73) 308 (74) 0.97
History of myocardial infarction 20 (18) 307 (16) 0.68 7 (16) 74 (17) 0.86
History of PCI 15 (13) 249 (13) 0.93 6 (13) 44 (10) 0.72
History of coronary artery bypass grafting 10 (9) 154 (8) 0.77 2 (4) 31 (7) 0.47
Peripheral vascular disease 14 (12) 186 (10) 0.34 5 (11) 43 (10) 0.65
History of stroke or TIA 9 (8) 107 (6) 0.33 5 (11) 46 (11) 0.96
Moderate to severe renal disease 3 (3) 51 (3) 0.85 2 (4) 21 (5) 0.82
Characteristics at the time of PCI
Pre-procedural shock 2 (2) 58 (3) 0.37 3 (7) 14 (3) 0.79
Unstable angina 73 (63) 1,212 (63) 0.98 23 (51) 208 (47) 0.54
Left ventricular ejection fraction, % 0.84 0.62
>40 60 (52) 995 (52) 19 (42) 196 (45)
<40 8 (7) 115 (6) 6 (13) 45 (10)
Unknown 47 (41) 820 (42) 20 (44) 197 (45)
No. of diseased vessels 0.32 0.044
1 37 (34) 670 (37) 11 (26) 140 (34)
2 40 (37) 704 (38) 16 (38) 161 (39)
3 31 (28) 427 (23) 15 (36) 100 (24)
Multivessel disease 73 (66) 1,155 (62) 0.52 31 (74) 270 (64) 0.19
Thrombus in any lesion 38 (34) 691 (37) 0.49 15 (36) 157 (39) 0.90
Bifurcation in any lesion 14 (13) 241 (13) 0.87 7 (17) 71 (17) 1.00
Ostial lesion 16 (17) 264 (17) 0.88 9 (25) 70 (18) 0.21
Pre-PCI TIMI ﬂow 0 or 1 any lesion 24 (28) 341 (24) 0.38 8 (22) 100 (26) 0.51
Urgency of PCI 0.11 0.85
Elective 48 (42) 653 (34) 14 (31) 139 (32)
Urgent 48 (42) 889 (46) 17 (38) 160 (36)
Emergent 19 (17) 388 (20) 14 (31) 141 (32)
Total no. of vessels treated 0.58 0.42
1 102 (89) 1,738 (90) 40 (89) 376 (86)
2 11 (10) 177 (9) 5 (11) 59 (13)
3 2 (2) 16 (1) 0 (0) 4 (1)
Total no. of stents placed 1.6  0.8 1.5  0.8 0.67 1.5  0.8 1.5  0.9 0.92
Drug-eluting stent use 31 (27) 502 (26) 0.69 27 (60) 263 (60) 1.00
PCI native LAD 46 (40) 721 (37) 0.52 19 (42) 211 (48) 0.58
PCI native LMCA 4 (3) 31 (2) 0.29 0 (0) 0 (0) —
PCI native RCA 52 (45) 902 (47) 0.75 17 (38) 186 (42) 0.32
PCI native left circumﬂex 27 (23) 417 (22) 0.69 14 (31) 108 (24) 0.31
PCI vein graft 2 (2) 52 (3) 0.44 0 (0) 2 (0) 0.56
Procedural success 115 (100) 1,907 (99) 0.10 44 (98) 437 (99) 0.26
Post-PCI TIMI ﬂow 3 in all lesions 108 (96) 1,815 (97) 0.34 43 (96) 409 (96) 0.93
Continued on the next page
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1414versus control membership. The propensity score was
modeled using logistic regression, using covariates
different between the patients and the control pa-
tients pool at the 0.25 signiﬁcance level. The date of
PCI and discharge medications were also included
in the model, regardless of the p value. A greedymatching algorithm was used to match control pa-
tients with patients with the following restrictions on
the control patient to be matched to a patient: pro-
pensity score must be within one-fourth of the pro-
pensity score SD of the patient, age must be within 5
years, exact match on sex, and PCI date within 2 years
TABLE 1 Continued
PCI Before EBRT
(n ¼ 115)
Control Patients
(n ¼ 1,930) p Value
EBRT Before PCI
(n ¼ 45)
Control Patients
(n ¼ 439) p Value
Medications at discharge after PCI
Aspirin 112 (97) 1,883 (98) 0.79 41 (95) 426 (98) 0.49
Thienopyridine 113 (98) 1,910 (99) 0.38 43 (96) 436 (99) 0.045
Lipid-lowering agent 86 (75) 1,460 (76) 0.72 34 (77) 352 (81) 0.76
ACE inhibitor 41 (36) 674 (35) 0.90 19 (43) 202 (46) 0.83
Beta-blocker 87 (76) 1,463 (76) 1.00 36 (82) 388 (89) 0.37
Values are n (%) or mean  SD. *There was no p value for male sex because the matching algorithm forced a perfect match between the groups.
ACE ¼ angiotensin-converting enzyme; EBRT ¼ external beam radiation therapy; LAD ¼ left anterior descending coronary artery; LMCA ¼ left main coronary artery; PCI ¼
percutaneous coronary intervention; RCA ¼ right coronary artery; TIA ¼ transient ischemic attack; TIMI ¼ Thrombolysis In Myocardial Infarction.
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1415of the patient. For patients with EBRT after PCI,
control patients had to survive at least as long as the
length of time from the patient’s PCI to the EBRT
date. As many as 20 control patients could be
matched per case. Summary statistics were weighted
so that each set of control patients for a particular
case contributed as much weight as any other set of
matched control patients. Stratiﬁed logistic regres-
sion was used to compare differences between pa-
tients and control patients, with each case/control(s)
set constituting separate strata. Time-to-event vari-
ables were compared between the 2 groups using a
Cox regression model, with separate strata for each
patient/control patient(s) set.
RESULTS
There were 13,508 patients treated with thoracic EBRT
involving the heart during the study period. Cross-
referencing these patients with the Mayo Clinic PCI
database resulted in a total of 334 patients who un-
derwent both EBRT and coronary artery stenting at our
institution from 1998 to 2012. After excluding dupli-
cate patients, those in whom EBRT was for palliative
intent (n ¼ 7), those with no or incomplete follow-up
(n ¼ 87), as well as those for whom we could not ﬁnd
appropriate matched control patients (n ¼ 80), a total
of 160 patients were ultimately selected for analysis.
OUTCOMES IN PATIENTS RECEIVING EBRT AFTER PCI.
Of the 160 patients identiﬁed, 115 had PCI before
receiving curative thoracic EBRT for cancer (group A)
with a median interval between the 2 events of 3.6
(interquartile range [IQR]: 4.9; [Q1,Q3] ¼ 1.7 to 6.5)
years. These patients were compared with a
propensity-matched control patient cohort of 1,930
patients without previous EBRT. Baseline clinical,
angiographic, and procedural characteristics at
the time of PCI (Table 1) were similar between the
EBRT-treated group and control patients, with theexception of a higher rate of hypertension in the
EBRT group (74% vs. 65%, p ¼ 0.04). Medication use
was similar between groups.
During a median follow-up period of 2.1 years
(IQR: 3.3; [Q1,Q3] ¼ 1.0 to 4.3 years), TLR rates were
similar between the 2 groups (3-year rate: EBRT,
3.2%; control patients, 6.6%; p ¼ 0.31) (Figure 1A,
Table 2). There were no signiﬁcant differences in rates
of MI (4.8% vs. 4.3%, p ¼ 0.93) (Figure 1B) or cardiac
death (2.3% vs. 3.6%, p ¼ 0.66) (Figure 1C). As ex-
pected, the cohort of cancer patients treated with
EBRT after PCI had a signiﬁcantly higher all-cause
mortality rate as demonstrated by Kaplan-Meier sur-
vival estimate (48.6% vs. 13.9%, p < 0.001) (Figure 1D)
compared with controls.
The matching of stent type (DES vs. BMS) between
patients and control patients was similar in the ma-
jority (83%) of patients (based on weighted controls).
Among the cohort of 115 EBRT-treated patients, there
was no signiﬁcant correlation between the primary
outcome TLR and the EBRT-PCI interval (p ¼ 0.63) or
stent type (DES vs. BMS) (p ¼ 0.37).
OUTCOMES IN PATIENTS WHO REQUIRED PCI
AFTER EBRT. A total of 45 cancer survivors were
treated with PCI at a median of 2.2 (IQR: 4.5;
[Q1,Q3] ¼ 0.6 to 5.1) years after EBRT (group B).
Compared with 439 matched control patients without
previous EBRT, baseline characteristics and discharge
medications were similar (Table 1).
Table 2 summarizes the clinical outcomes in group
B. Overall, after a median of 3.1 years of follow-up
(IQR: 3.5; Q1,Q3 ¼ 1.5 to 5.1), rates of TLR (3-year
rate: EBRT patients, 9.2%; control patients, 9.7%;
p ¼ 0.79 (Figure 2A), MI (4.6% vs. 9.3%, p ¼ 0.66)
(Figure 2B), cardiac death (6.8% vs. 3.4%; p ¼ 0.30)
(Figure 2C), and all-cause death (27.4% vs. 22.0%) (p ¼
0.35) (Figure 2D) were similar between both groups.
The type of stent used (DES or BMS) in the patients
treated with stenting after EBRT matched 100% of
FIGURE 1 Three-Y
Kaplan-Meier surviva
overall survival (D).
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1416the time with the control patients. Among the cohort
of 45 EBRT-treated patients, there was no signiﬁcant
correlation between the interval between EBRT-PCI
(p ¼ 0.59) or stent type (DES vs. BMS) (p ¼ 0.88)
with the primary outcome TLR.
DISCUSSION
The major and novel ﬁnding of this study of patients
with concomitant CAD treated with PCI and cancer
requiring thoracic EBRT is that the latter is not asso-
ciated with increased rates of stent failure. This is
important given the otherwise well-known delete-
rious cardiac side effects of thoracic EBRT.ear Outcomes After External Beam Radiation Therapy in Patients With Pre
l curves demonstrating freedom from target lesion revascularization (A), fre
RT ¼ radiation therapy.RADIATION THERAPY AS TREATMENT FOR CAD.
Intracoronary radiotherapy has previously been
used as an adjunctive therapeutic option in the
management of patients with CAD treated with PCI.
Animal studies have demonstrated that intravascular
radiotherapy may reduce restenosis after balloon
injury by inhibiting neointimal formation (6) and
preventing late adventitial ﬁbrosis (7). Adjunctive
coronary brachytherapy was once the preferred
therapy for in-stent restenosis to prevent recurrence
in patients with BMS (8,9). However, long-term
follow-up of intracoronary brachytherapy conﬁrmed
a risk of delayed stent failure, and hence, this
approach is no longer used (3,4).vious Stenting (Group A)
edom from myocardial infarction (MI) (B), cardiac survival (C), and
TABLE 2 Primary and Secondary Outcomes After PCI and EBRT
Stent
Before EBRT
(n ¼ 115)
Control
Patients
(n ¼ 1,930) p Value
EBRT
Before Stent
(n ¼ 45)
Control
Patients
(n ¼ 439) p Value
TLR 0.31 0.79
30 days 0 (0) 9 (0.5) 0 (0) 1 (0.2)
180 days 0 (0) 31 (1.7) 4 (9.2) 24 (5.7)
270 days 0 (0) 41 (2.2) 4 (9.2) 26 (6.0)
1 yr 0 (0) 50 (2.7) 4 (9.2) 28 (6.5)
2 yrs 2 (3.2) 81 (4.8) 4 (9.2) 35 (8.6)
3 yrs 2 (3.2) 104 (6.6) 4 (9.2) 38 (9.7)
Myocardial infarction 0.93 0.66
30 days 0 (0) 3 (0.1) 0 (0) 7 (1.6)
180 days 0 (0) 14 (0.8) 2 (4.6) 25 (5.7)
270 days 0 (0) 27 (1.5) 2 (4.6) 26 (6.1)
1 yr 0 (0) 38 (2.1) 2 (4.6) 27 (6.2)
2 yrs 2 (3.0) 54 (3.2) 2 (4.6) 36 (8.7)
3 yrs 3 (4.8) 69 (4.3) 2 (4.6) 38 (9.3)
Cardiac mortality 0.66 0.30
30 days 0 (0) 0 (0) 1 (2.2) 2 (0.4)
180 days 1 (1.0) 7 (0.4) 2 (4.4) 5 (1.2)
270 days 1 (1.0) 13 (0.7) 3 (6.8) 5 (1.2)
1 yr 1 (1.0) 16 (0.9) 3 (6.8) 6 (1.3)
2 yrs 2 (2.3) 33 (2.0) 3 (6.8) 8 (2.0)
3 yrs 2 (2.3) 54 (3.6) 3 (6.8) 12 (3.4)
Overall mortality <0.001 0.35
30 days 0 (0) 13 (0.7) 1 (2.2) 4 (0.9)
180 days 7 (6.3) 45 (2.4) 3 (6.7) 15 (3.4)
270 days 12 (10.9) 63 (3.3) 5 (11.1) 21 (4.7)
1 yr 19 (17.4) 78 (4.1) 6 (13.3) 25 (5.7)
2 yrs 36 (34.7) 172 (9.8) 11 (24.4) 74 (17.9)
3 yrs 48 (48.6) 230 (13.9) 12 (27.4) 88 (22.0)
Values are n (%).
TLR ¼ target lesion revascularization; other abbreviations as in Table 1.
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1417The effect of EBRT on vascular stents remains un-
clear. Animal and human studies have found variable
effects of EBRT on preventing stenosis in coronary
and noncoronary arteries after arterial injury and
stenting. Some studies have reported a dose-
dependent inhibitory effect of EBRT on the develop-
ment of intimal hyperplasia after balloon injury to
animal carotid arteries (10,11). Conversely, other
studies have demonstrated increased neointimal
formation in the coronary and iliac arteries with low-
dose (<16 Gy) EBRT, possibly due to up-regulation of
extracellular matrix expression (12,13). Contrarily,
Verheye et al. (14) reported a beneﬁcial effect of high-
dose (21 Gy) EBRT on pig hearts immediately after
BMS implantation, resulting in a signiﬁcant increase
in lumen area and reduction in neointima formation.
In another study in pigs, coronary EBRT resulted in
increased neointimal and adventitial collagen
compared with intracoronary radiotherapy, and focal
interstitial necrosis in the adjacent myocardium was
only seen in the EBRT-treated pigs (15). Prospective
studies examining the effect of EBRT have not been
performed with human coronary artery stents, but
EBRT has been shown to decrease rates of restenosis
in human peripheral arterial stents (16,17).
EBRT AFTER STENTING FOR CAD. In the present
study, we demonstrate no increase in clinically sig-
niﬁcant in-stent restenosis or stent thrombosis in
patients who are treated with EBRT, as evidenced by
similar rates of TLR, MI, and cardiac mortality. Pre-
vious human and animal studies examining the ef-
fects of EBRT after angioplasty and stenting involved
EBRT treatment immediately after the arterial inter-
vention, and therefore the ﬁndings cannot be
extrapolated to patients who are treated with EBRT
months or years after stenting. To our knowledge, our
study is the ﬁrst to examine the effect of delayed
EBRT in patients with coronary artery stents.
In current practice, radiation oncologists do not
typically alter the radiation doses or treatment plans
based on the presence or location of coronary artery
stents, and our results are reassuring in that the
indiscriminate use of EBRT without using coronary
artery–sparing techniques in these patients does not
place them at increased risk of worse long-term car-
diac outcomes. As expected, the patients with EBRT
in our study had worse overall survival compared
with the non-EBRT group. Because cardiac mortality
remained unchanged, this increased noncardiac
mortality is likely attributed to the underlying ma-
lignancy for which patients received the EBRT. Based
on our results, clinicians need not be as concerned
about the stent-toxic effects of EBRT and shouldinstead aim to treat the underlying malignancy as the
priority.
EBRT BEFORE STENTING. The outcomes after coro-
nary artery stenting in cancer survivors previously
treated with EBRT were reported in 2 previous studies
(18,19). Dubois et al. (18) reported in their retrospec-
tive study that patients with previous thoracic EBRT
for lymphoma, lung, or breast cancer who later un-
derwent coronary artery stenting had higher rates of
all-cause (hazard ratio: 4.2, p ¼ 0.0006) and cardiac
(hazard ratio: 4.2, p ¼ 0.00451) mortality. However,
similar to our ﬁndings, they saw no signiﬁcant dif-
ference in clinical presentation for in-stent reste-
nosis, with similar rates of TLR, acute MI, and stent
thrombosis in those previously treated with EBRT. As
such, it is unlikely that the increased cardiac or all-
cause mortality is directly related to stent failure.
Rather, the presence of underlying malignancy was a
likely confounding factor for the higher all-cause
mortality rate, and the previous use of cardiotoxic
FIGURE 2 Three-Year Outcomes After Percutaneous Coronary Intervention and Stenting in Patients With Previous Thoracic External Beam
Radiation Therapy (Group B)
Kaplan-Meier survival curves demonstrating freedom from target lesion revascularization (A), freedom from MI (B), cardiac survival (C), and overall survival (D).
Abbreviations as in Figure 1.
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1418chemotherapeutic agents including anthracyclines
may have contributed to the higher rates of cardiac
mortality.
In a retrospective analysis, Schomig et al. (19) re-
ported a smaller cases series of patients who under-
went coronary stenting using BMS and underwent
follow-up coronary angiography after 6 months.
They compared rates of angiographic restenosis in 14
lymphoma survivors who had received previous
EBRT versus 6 lymphoma survivors who had never
received EBRT, and 10,032 control patients with no
history of lymphoma. Angiographic stent restenosisoccurred more frequently in the lymphoma survivors
with previous EBRT (85.7%) compared with those
with lymphoma and no EBRT (16.7%) and those with
no history of lymphoma or EBRT (25.5%) (19). In
contrast to the results of our study as well as those
reported of the aforementioned study by Dubois et al.
(18), the rates of TLR reported by Schomig et al. (19)
were higher in the EBRT group (66.6% vs. 14.2% and
18.0%, p < 0.001), a ﬁnding possibly attributed to the
oculostenotic reﬂex or angiographically versus clini-
cally driven TLR (18). Moreover, in contrast to our
investigation, the study by Schomig et al. (19) had a
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1419smaller sample size, was limited to a single type of
malignancy, and had an unmatched control group.
Thus, based on the data available to date, it is likely
that previous EBRT does not increase stent failure
in the broader population of patients with thoracic
malignancies but may predispose to subclinical
restenosis.
STUDY LIMITATIONS. Due to the retrospective design
of our study, our results should be considered
exploratory and hypothesis generating. It is impor-
tant to note that although all patients in our study
underwent both PCI and EBRT within a 14-year study
period, radiation cardiotoxicity including CAD may
occur decades after the initial EBRT treatment course.
For example, 1 study demonstrated that the median
time to diagnosis of CAD in Hodgkin lymphoma
survivors after EBRT was 15.8 years (20). As such, our
results may not be applicable to those patients
with long intervals between EBRT and PCI, as our
EBRT-treated cohort may have had preexisting CAD
before the EBRT, and plaque quality may be different
than in those with CAD attributed solely to EBRT.
Future studies with longer EBRT-PCI intervals would
be helpful to elucidate whether rates of stent failure
differ in those patients. For the patient–control pa-
tient comparisons in both EBRT groups, the case
populations were inherently different compared with
the controls because they all had treated or active
malignancy, which was not always the case in the
controls. The presence of malignancy and use of
cardiotoxic chemotherapy may have been con-
founders when analyzing outcomes in our analysis.
We included a small number of patients treated with
intensity-modulated radiotherapy and stereotactic
body radiation therapy, 2 increasingly used EBRTtechniques that are thought to better spare the heart
and lungs. The long-term cardiotoxic effects of these
2 techniques have not been well studied and merit
further investigation. Finally, the small sample sizes
and low event rates (except for all-cause mortality) in
our patient cohorts were a limitation as well, and
there was inadequate power to identify whether
EBRT resulted in differential effects on stent failure
rates based on stent type (DES vs. BMS).
CONCLUSIONS
Our ﬁndings suggest that treatment with thoracic
EBRT does not increase the risk of the development of
clinically signiﬁcant stent failure in patients with
cancer who are treated with coronary artery stents
either before or after EBRT. EBRT need not be with-
held in patients with coronary stents, and the use of
coronary artery–sparing EBRT in these patients ap-
pears to be unnecessary. The emphasis in these pa-
tients should be on eradicating the underlying
malignancy. In addition, PCI with stents may be
safely used as a treatment option for CAD in cancer
survivors previously treated with EBRT. This is
highlighted by the fact that patients with radiation-
associated heart disease have increased long-term
mortality after cardiac surgery, and some in-
vestigators have suggested that alternative treatment
strategies may be more appropriate (21).
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